Brain Cancer Trials

AbbVie

AbbVie: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

Purpose

This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) prolongs progression free survival (PFS) and overall survival (OS) in participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.

Eligibility

Must have a diagnosis of Glioblastoma and have had no prior treatment.

Learn more about study.

N0577

N0577:  Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Purpose

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.

Eligibility

This study is looking for patients recently diagnosed with Anaplastic Glioma or Low Grade Glioma.

Learn more about study

NRG-BN001 

NRG-BN0

01:  Randomized Phase II Trial of Hypofractionated Dose-escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Purpose

This trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma.

Eligibilty

This study is looking for patients diagnosed with a glioblastoma.

Learn more about study.

For more information about cancer-related clinical trials, call (260) 425-6800 and ask to speak to a clinical research coordinator. You may also e-mail oncologyresearch@parkview.com.

Parkview Cancer Institute
11050 Parkview Circle
Fort Wayne, Indiana 46845

Search By Cancer Type

 

Need assistance?

Contact us